Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 10/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.37 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224747 | 0.84 | SRC (0.47) | BRAF | |
| SCHEMBL7249188 | 0.82 | MAP2K1 (0.46) | TGFBR1MAP4K4APPALK | |
| SCHEMBL7247623 | 0.75 | SRC (0.56) | APP | |
| SCHEMBL5259570 | 0.74 | MAP2K1 (0.47) | — | |
| SCHEMBL3225436 | 0.69 | MAP2K1 (0.62) | — | |
| SCHEMBL3223606 | 0.67 | MELK (0.42) | BRAF | |
| SCHEMBL3228774 | 0.65 | MAP2K1 (0.49) | — | |
| SCHEMBL3221025 | 0.64 | SRC (0.59) | — | |
| SCHEMBL3225370 | 0.63 | MAP2K1 (0.49) | — | |
| SCHEMBL4418535 | 0.63 | PPARA (0.47) | MAP4K4BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | TGFBR1 1241/4885MAP4K4 34/4885BRAF 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.